12/10/2026
A newly published study just made inflammatory pain research more interesting by putting CBN and THCV beside C*D instead of letting isolated C*D carry the whole cannabinoid conversation.
“Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain” (May 2026) found that C*D, CBN, and THCV all reduced mechanical pain sensitivity in rats with knee inflammation, while CBN also reduced heat sensitivity and THCV helped restore body weight.
In plain language, these cannabinoids showed pain-related effects in an inflammatory pain model, but they didn't all act the same way.
Researchers used a CFA knee-injection model in male rats to create joint inflammation, tissue damage, reduced movement, increased mechanical pain, and some thermal sensitivity. One week later, the rats received four daily doses of ibuprofen, C*D, CBN, or THCV.
The goal was to see whether these plant cannabinoids could reduce inflammatory pain and how they compared with a common anti-inflammatory drug.
The strongest takeaway is that CBN and THCV stood out. All three cannabinoids reduced mechanical hyperalgesia, but CBN also lowered thermal hypersensitivity. CBN and THCV helped recover body weight in the inflamed animals, while C*D reduced body weight and raised blood monocyte and granulocyte levels above the inflamed control group.
That doesn't make C*D bad. It means different cannabinoids may behave differently depending on the pain model, dose, immune state, and biology involved.
For consumers, this study does not prove that CBN or THCV treats arthritis or inflammatory pain in humans. It does show why cannabinoid science needs to move beyond one-cannabinoid thinking.
For industry and researchers, CBN and THCV deserve deeper study in inflammatory pain, especially where pain, immune activity, and movement are all part of the same problem.
-Mike Robinson, Global Cannabinoid Research Center
Study: https://doi.org/10.1038/s41598-026-51275-7